Mirum Pharmaceuticals Inc Forecast, price target & analysts
Mirum Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Mirum Pharmaceuticals Inc Classifications & Recommendation:
Mirum Pharmaceuticals Inc Price Target
| Target Price | $65.44 |
| Price | $46.98 |
| Potential |
39.32%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Mirum Pharmaceuticals Inc 2026 .
The average Mirum Pharmaceuticals Inc target price is $65.44.
This is
39.32%
register free of charge
$74.00
57.53%
register free of charge
$55.00
17.08%
register free of charge
|
|
| A rating was issued by 9 analysts: 9 Analysts recommend Mirum Pharmaceuticals Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Mirum Pharmaceuticals Inc stock has an average upside potential 2026 of
39.32%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 186.37 | 334.42 |
| 141.85% | 79.44% | |
| EBITDA Margin | -52.76% | -17.39% |
| 68.12% | 67.04% | |
| Net Margin | -102.96% | -24.24% |
| 58.86% | 76.46% |
9 Analysts have issued a sales forecast Mirum Pharmaceuticals Inc 2024 . The average Mirum Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Mirum Pharmaceuticals Inc EBITDA forecast 2024. The average Mirum Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Mirum Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Mirum Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.00 | -1.69 |
| 0.50% | 57.75% | |
| P/E | negative | |
| EV/Sales | 7.27 |
2 Analysts have issued a Mirum Pharmaceuticals Inc forecast for earnings per share. The average Mirum Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Mirum Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Mirum Pharmaceuticals Inc...
Current Mirum Pharmaceuticals Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Baird | Locked ➜ Locked | Locked | Feb 27 2025 |
| Citizens Capital Markets | Locked ➜ Locked | Locked | Feb 24 2025 |
| Baird | Locked ➜ Locked | Locked | Nov 13 2024 |
| Citigroup | Locked ➜ Locked | Locked | Nov 13 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 13 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Oct 17 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Baird: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Citizens Capital Markets: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Baird: Locked ➜ Locked
|
Nov 13 2024 |
|
Locked
Citigroup: Locked ➜ Locked
|
Nov 13 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 13 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Oct 17 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
